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MR Imaging
At MR imaging, types A, AB, and B1 thymomas have similar or 
slightly higher signal intensity (SI) than that of muscle on T1-weighted 
images (T1WI) and higher SI than that of muscle on T2-weighted 
images (T2WI) (4, 6, 9-12). At Gd-DTPA enhanced MR imaging, 
homogeneous and moderate enhancement is observed. Most B2 and B3 
thymomas manifest inhomogeneous SI with scattered high-intensity ar-
eas on T2WI, which are corresponded to cystic spaces with or without 
hemorrhage on pathologic examination (6). In a study by Sakai et al 
(6), T2WI indicated that six of 12 invasive thymomas (probably WHO 
type B2 or B3) had lobular internal architecture, with 1- to 2-mm-thick 
low SI lines; for the ﬁve benign thymomas (probably WHO type A, 
AB, B1), this was not, however, the case. Unlike types A, AB, B1, B2, 
and B3 tumors, thymic carcinomas show relatively low SI at both T1- 
and T2WI, appearing as slightly inhomogeneous lesions (12).
FDG- PET
In TET, FDG-PET may be useful in differentiating thymic carcinoma 
from other thymic tumors, thymic hyperplasia, and normal physiologic 
uptake (13). Sasaki et al (7) reported that the standardized uptake value 
(SUV) for thymic carcinoma was signiﬁcantly greater than that for 
invasive or non-invasive thymoma. With an SUV cutoff point of 5.0, 
thymic carcinoma can be differentiated from thymoma with reasonably 
high sensitivity (84.6%), speciﬁcity (92.3%), and accuracy (88.5%). 
There was no statistically signiﬁcant difference in SUV between inva-
sive and non-invasive thymomas.
Conclusions
An awareness of the various imaging ﬁndings of the different types of 
TET, as reﬂected in the WHO histologic classiﬁcation, may be helpful in 
clinical practice for the assessment and treatment of patients with TET.
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Background: Thymoma, thymic carcinoma, and thymic carcinoid 
are derived from the epithelium of the thymus, and are described as 
Thymic epithelial tumors. These neoplasms are well-known for het-
erogeneity in the oncological behaviors, variability in the histological 
appearance, and association with autoimmune diseases represented by 
myasthenia gravis. The main strategy of treatment for thymic epithelial 
tumors is supposed to be surgical resection. There have been many 
reports studying prognostic factors including Masaoka staging system, 
completeness of resection, size of the tumor, the involved organs, and 
association with myasthenia gravis. On the other hand, pathological 
classiﬁcation of thymic epithelial tumors has been confusing and the 
clinical signiﬁcance of histological appearance has been unclear. World 
Health Organization (WHO), however, established a consensus on the 
histological classiﬁcation of the thymic epithelial tumors in 1999.
Aim: We aimed to elucidate the prognostic factors responsible for 
survival, and examined the outcome of surgical treatment based on 272 
patients between 1957 and 2001.
Results: The number of patients according to Masaoka stage is 113 in 
stage I, 64 in stage II, 71 in stage III, 11 in stage IVa, and 13 in stage 
IVb. The number of patients according to World Health Classiﬁcation 
system is 17 in type A, 65 in type AB, 50 in type B1, 89 in type B2, 23 
in type B3 and 28 in type C. 
The proportion of invasive tumor was 11%, 42%, 47%, 69%, 85%, 
and 94%, in type A, AB, B1, B2, B3, and C tumor, respectively. The 
proportion of tumors with involvement of the great vessels was 0%, 
4%, 7%, 17%, 19% and 43% in type A, AB, B1, B2, B3, and C tumor, 
respectively. The proportion of association with myasthenia gravis was 
0%, 7%, 40%, 56%, 10%, and 0% in type A, AB, B1, B2, B3, and C 
tumor, respectively.
According to Masaoka staging system, 10-year survival rate was 99%, 
95%, 91%, 36% and 0% in stage I, II, III, IVa and IVb disease, respec-
tively. According to WHO histological classiﬁcation system, 10-year 
survival rate was 100%, 96%, 97%, 92%, 78% and 68% in type A, AB, 
B1, B2, B3, and C tumor, respectively.
Multivariate analysis was done to determine the independent prognos-
tic factor in thymomas. Masaoka staging system and WHO histologic 
classiﬁcation were the signiﬁcant factors while age, gender, association 
with myasthenia gravis, completeness of resection or involvement of 
the great vessels were not.
Conclusion: Stage and histology are signiﬁcant prognostic factors and 
should be considered when determining the strategy for treatment.
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Pre-operative Radiation Therapy
For locally advanced, large, invasive thymomas that are unresectable or 
marginally resectable, preoperative adjuvant radiation therapy has been 
advocated to render it resectable. Several studies on limited numbers of 
